967 A Prognostic Model of Therapy-Related Myelodysplastic Syndrome for Predicting Survival and Transformation to Acute Myeloid Leukemia
http://ash.confex.com/ash/2011/webpr...aper39970.html
"Background: A significant fraction of patients with MDS have a prior history of an antecedent malignancy treated with chemotherapy and/or radiotherapy. Therapy related MDS (t-MDS) differs from de novo MDS in its high frequency of chromosomal abnormalities (typically in the context of complex karyotypes), high rate of transformation to acute myeloid leukemia (AML), and high resistance to standard MDS therapy. MDS prognostic models (e.g., IPSS, WPSS) have been developed based primarily on cohorts of patients with de novo MDS. We evaluated the characteristics of a large cohort of patients with t-MDS and created a specific t-MDS prognostic model."
There are typical differences between t-MDS and novo MDS.
1. In t-MDS - many patients with chromosomal abnormalities, typically within complex karyotypes
2. In t-MDS - high rate of transformation to acute myeloid leukemia (in MDS the rate is not so high in de novo MDS- patients)
3. In t-MDS in many cases the standard MDS-therapies don`t help
"Conclusion: We propose a prognostic model specific for patients with t-MDS that predicts overall and leukemia-free survivals. This model may facilitate the development of risk-adapted therapeutic strategies."
There is a prognostic model proposed in this study report for patients with t-MDS. This could be helpful to choose the best therapies for these patients (perhaps not so long watch-and-wait, earlier onset of medical therapies..)
This model does not give a prognosis for the overall-chances of t-mds-patients, but helps to optimize treatments
Margarete